



Late-Breaking Clinical Trials and Science Submission Guidelines

The Heart Rhythm Society recognizes that stimulating and rapidly developing research may not have been completed in time for the December 2023 abstract submission deadline. To highlight this timely and innovative work at Heart Rhythm 2024, the Heart Rhythm Program Committee will develop peer-reviewed sessions consisting of late-breaking science and late-breaking clinical trials.

Important Information

The Late-Breaking submission site will open **Friday, January 19th, 2024**. Each submission will require a fee of \$175 for HRS members and \$250 for non-members. This fee will be charged to the submitting author for each abstract submitted. The submission fee will directly fund additional travel grants to assist fellows-in-training and support enhancements to the presentation of abstracts. Payments must be made by credit card during the submission process. Visa, MasterCard, and American Express are accepted.

All submissions must be received no later than **Friday, March 1st, 2024, at 11:59 PM Eastern Time**. Abstracts submitted after the deadline will not be considered. *Submitting authors will be notified about the acceptance/rejection of their abstract via email by March 15th, 2024.*

Abstract Author Designation

Abstract authors can be comprised of three distinct types:

- **Submitting Author:** the author who officially submits the abstract to the Heart Rhythm 2024 Abstract Submission Site. The submitting author does not have to be the first author and does not have to be the presenting author. However, all correspondence regarding the abstract submission and decision will be directed to the submitting author. This information should be reviewed to ensure that the current and correct email address is provided.
- **Presenting Author:** the author, regardless of author order, who will present the abstract, should it be accepted for presentation at Heart Rhythm 2024. *Please note that the submitting author or first author is not automatically assigned as the presenting author.* The presenting author must be designated in the submission as shown below (here, you can see that the first author is not designated as the presenting author).

AUTHOR ORDER	PRESENTER	AUTHORS	REMOVE AUTHOR
1	<input type="radio"/>	Ms. Vanessa Lopez - More Info	Remove
		<input type="button" value="+ Show Affiliations"/> *Affiliation Edit <input type="text" value="Heart Rhythm Society"/> Edit Remove	
2	<input checked="" type="radio"/>	Sarah Albright Alfano - More Info	Remove
		<input type="button" value="+ Show Affiliations"/> *Affiliation Edit <input type="text" value="Heart Rhythm Society"/> Edit Remove	

- **Co-author(s):** all additional authors contributing to the abstract.

The Society will institute the “Author Search” tool for abstract submissions. This will allow you to search the HRS database for your co-authors. For consistency, spell out all co-author names and avoid using initials. This will allow the correct information to appear in the index of all Heart Rhythm 2024 publications, website, and mobile applications. If an individual is not in our database, they will be required to set up an HRS account. It is strongly encouraged that all abstract co-authors create an HRS account prior to abstract submission and author search.

To avoid scheduling conflicts, an abstract author may serve as the Presenting Author for no more than five (5) abstracts.

Investigator/Presenting Author Requirements

- Only one investigator per trial can be considered the presenter.
- The submitting investigator must guarantee that all co-authors are familiar with the data, agree with the stated results, have agreed to be included as authors, and have given final approval of the submitted abstract.
- If an investigator belongs to multiple submissions, the investigator’s name must be identical in each submission. This will ensure consistency and assist in the indexing process for all Heart Rhythm 2024 publications.
- A completed submission constitutes a commitment by an investigator to present it if accepted. All presentations will be conducted live in Boston, MA. There will not be an option for virtual or pre-recorded presentation.

*Please note that while the Submitting Author will receive correspondence regarding the **acceptance decision** for the abstract, the Presenting Author is the one who will receive the official **invitation to present** as well as further details including presenter resources, session details, and scheduling information. Please make sure to review your author list and have the correct presenting author identified prior to submission. In the event that the Presenting Author is unable to present, a co-author can be identified to present in his/her place after contacting HRS staff to request this change.*

Criteria

Evaluation will be based on the following criteria:

1. Impact of the research
2. Novelty and rigor of the study design

3. Clinical endpoints
4. Quality of the statistical plan

Rules for Submission Eligibility

- If an abstract submission has already been accepted for the Heart Rhythm 2024 meeting, it will need to be withdrawn if accepted as a Late-Breaking abstract submission.
- Submissions are not eligible for consideration if the manuscript of the submission will be published prior to Heart Rhythm 2024 (May 16 – 19, 2024).
- Submissions are not eligible for consideration if the trial results have been presented at a major international meeting held prior to Heart Rhythm 2024 (May 16 – 19, 2024).
- Submissions that appear to be redundant versions of a single study and/or selling a product versus discussing science will be rejected.

Late-Breaking Clinical Trials and Science Categories

1. **Late-Breaking Randomized Clinical Trials:** First-time presentation of primary or major secondary results from a prospective, randomized clinical trial.
2. **Late-Breaking Clinical Innovations:** First-time presentation of results of clinical applications of novel therapeutic or diagnostic approaches to heart rhythm disorders.
3. **Late-Breaking Clinical Trials Updates and Registries:** Follow-up analyses from prospective, randomized clinical trials or first-time presentation of high-impact information from multicenter clinical registries or observational studies.
4. **Late-Breaking Science:** Innovative research that includes the latest breakthroughs in basic and/or clinical science that could have a significant impact on clinical practice.

ABSTRACT SUBMISSION AND PREPARATION GUIDELINES

Abstract Title

- An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.
- Titles should **not** include the authors' names.
- Always use the correct title case (e.g., Only the Best of the Best in Medicine Study Electrophysiology).
- The abstract title is not counted in the character count limit (2,500) designated for abstract submission.

Abstract Text

When entering text, please remember:

- Use generic drug names.
- Do not begin sentences with numerals; numbers should be spelled out.
- Standard abbreviations may be used without definition. Non-standard abbreviations (which should be kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
- Do not include references, credits, or grant support.
- Do not include the names or personal information of any patient participating in the study or trial.

Please note that because of the text box system, you will not be able to upload your abstract into the submission site. You must either type the text in or cut and paste the text from another document. You will still be able to upload images.

Abstract Data

- Multiple abstracts appearing to be redundant versions of a single study will be rejected.

- Abstracts are not eligible for consideration if published prior to Heart Rhythm 2024. No abstract may be presented at Heart Rhythm 2024 if it is substantially similar to material presented or to be presented at a major international meeting held prior to Heart Rhythm 2024.
- Individuals who have submitted abstracts to other major international meetings and await notification of acceptance may also submit abstracts to the Heart Rhythm Society for Heart Rhythm 2024; however, upon acceptance from another organization, it is the responsibility of the submitting author to notify the Heart Rhythm Society by **April 8th, 2024** to withdraw the abstract.
- The Heart Rhythm 2024 Program Committee endorses the position of the American Association for the Advancement of Science in requiring assurances of the responsible use of animals in research ([AAAS Resolution: Use of Animals in Research, Testing, and Education](#)). All submissions must follow these guidelines.
- Any human experimentation must conform to the principles of the Declaration of Helsinki of the World Medical Association ([WMA Declaration of Helsinki](#)).
- The Presenting Author must ensure that all co-authors are familiar with the data, agree with the stated results, have agreed to be included as authors, and have given final approval of the submitted abstract.
- **Industry Abstract Submissions:** All submissions are required to focus on science and research and not products or services. Abstract presentation may not be sales presentations and/or endorsement for products or services.
- The Heart Rhythm Society reserves the rights of reproduction, distribution, display and derivatives in both print and digital format. Upon their abstract's acceptance, authors will be asked to read and comply with the Heart Rhythm Society's Release and Authorization for Webcasts, and Enduring Products.
- SEC Exception: A publicly traded company may determine that it is legally required to disclose certain data or other information from a confidential abstract in advance of the public release date to satisfy requirements of the U.S. Securities and Exchange Commission or a corresponding regulatory body in a country where the company's stock is traded (collectively, "SEC"). This need typically arises when there is a substantial likelihood that the information would be considered by a reasonable investor in the company to significantly alter the total mix of information made available to the investor. The abstract is still eligible for inclusion at the Heart Rhythm 2024 meeting provided that the company submits to HRS, in advance of the release, a letter signed by the company's legal counsel that contains the abstract title, indicates the format/nature of the public disclosure, and advises that (a) public disclosure of the information is necessary for the company to comply with applicable securities laws, and (b) the information disclosed is the minimum necessary for such compliance. HRS also requires that the lead author be copied on the request.

Abstract Format

The total number of characters allowed for the submission is 2,500. This character count does include spaces and does not include the abstract title. Figure and table files will reduce the character count by a maximum of 560 characters each based on size of image file.

Section Headers

Introduction:

Methods:

Results:

Application:

Next Steps/Future:

Graphics/Figures

1. Keep figures simple – line or bar graphs are most appropriate.
2. Ensure text is large enough to read when printed.
3. Use only pre-sized .gif or .jpg.
4. Save color images in RGB mode.
5. Ensure images are at least 300 dpi.
6. You are limited to one figure and one table per submission, submitted as image files.

Abstract Revisions

- Carefully proofread the abstract content and make any necessary revisions before the submission deadline.
- Resubmission of an abstract that is corrected or changed is not possible after the submission deadline.
- There will be a period of open editing between the time of notification and the withdrawal deadline; however, the only edits that will be accepted are to the author list. No edits to the abstract itself will be possible.

Accepted Submissions

General Information

- Acceptance/Rejection Notification: Announcements will be sent via email by **March 15th, 2024**, to the submitting author.
- Accepted Late-Breaking abstracts are embargoed until the morning of presentation. This means that the Society will release these abstracts on the day of the presentation.
- The Heart Rhythm Society reserves the rights of reproduction, distribution, display and derivatives in both print and digital format. Co-authors reserve all proprietary rights other than copyright, such as patent rights and the right to use all or part of the application in future works of their own.
- Titles and presenters will be listed online in the Heart Rhythm 2024 Program/Online Planner.
- The Late-Breaking abstracts will be published on the Heart Rhythm website shortly after the embargo lifts during the Heart Rhythm 2024 meeting and will be included in an upcoming issue of the *Heart Rhythm* journal.
- Authors of accepted abstracts are encouraged to submit full articles of their findings to *Heart Rhythm* for expedited peer review and potential publication in the journal either simultaneously with or soon after the presentation. See the *Heart Rhythm* [author guidelines](#) for more information on manuscript preparation and submission.
- Disclosure of relationships: the presenting author will be required to provide the Heart Rhythm Society with all financial relationships with ACCME-defined ineligible companies.

Registration

- The presenting author is required to register for Heart Rhythm 2024 and will be charged a reduced registration rate. This discount will be applied automatically to accepted presenting authors.
- Expenses associated with the submission and presentation of an abstract are the responsibility of the presenter.
- Only one author per abstract is considered the presenter. Co-author(s) listed on the abstract do not receive reduced rates towards registration.

Questions? If you have questions about submitting a Late-Breaking abstract for presentation at Heart Rhythm 2024, please contact HRS Staff at abstracts@hrsonline.org.